Practical Aspects of Including Functional Endpoints in Developmental Toxicity Studies. Case Study: Immune Function in HuCD4 Transgenic Mice Exposed to anti-CD4 MAb In Utero

  • Publication Date :
  • Publication Type : Journal Article
  • Author(s) : Herzyk DJ, Bugelski PJ, Hart TK, Wier PJ
  • Journal Name : Human and Experimental Toxicology

Human and Experimental Toxicology. 2002;21(9-10):507-512

Abstract: Keliximab is a human-cynomolgus monkey chimeric (Primatized) monoclonal antibody with specificity for human and chimpanzee CD4. As the preclinical safety assessment of biopharmaceuticals requires evaluation in pharmacologically responsive species, comprehensive toxicology studies, including reproductive toxicity, of this antibody were conducted in a human CD4 transgenic mouse model. The reproductive toxicology studies included a preand postnatal development study that incorporated immunotoxicological evaluation of offspring (F1) mice. The potential effects of exposure to treating maternal mice (F0) with keliximab during pregnancy and lactation on offspring viability, physical growth, neurobehavioral development, reproductive function, lymphoid tissue morphological structure, lymphocyte subsets and host resistance to Candida albicans infection were assessed. The results showed no impairment of these functions. The use of F1 transgenic mice in study with keliximab provides an example of a novel practical approach to assess developmental immunotoxicity within a study of preand postnatal development designed in accordance with ICH Guidelines.

To view the full citation, click here.

Contact Us

Health and Environmental Sciences Institute (HESI)
Phone: +1-202-659-8404
Fax: +1-202-659-3859

740 15th Street NW, Suite 600
Washington, DC 20005

Stay Informed

Sign up for our monthly e-newsletter.